SCHEMBL6989769

SCHEMBL6989769

CCOC(=O)c1ccc(CCC(O)CNC(=O)OC(C)(C)C)s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
SYK P43405 1/20 0.38
SERPINE1 P05121 1/20 0.38
ALDH1A1 P00352 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ABCB1 P08183 1/20 0.34
MAPT P10636 3/20 0.34
KDM4E B2RXH2 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
S1PR1 P21453 1/20 0.34
S1PR3 Q99500 1/20 0.34
TDP1 Q9NUW8 2/20 0.34
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
ATM Q13315 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6989772 1.00 HDAC3 (0.41) HDAC3HDAC4HDAC1HDAC6SYK
SCHEMBL6992685 1.00 HDAC3 (0.41) HDAC3HDAC4HDAC1HDAC6SYK
SCHEMBL7029394 0.90 NPSR1 (0.40) SYKSERPINE1MAPTNPSR1S1PR1
SCHEMBL8685235 0.88 HDAC3 (0.40) HDAC3HDAC4HDAC1HDAC6SYK
SCHEMBL8689908 0.88 HDAC3 (0.40) HDAC3HDAC4HDAC1HDAC6SYK
SCHEMBL8685226 0.88 HDAC3 (0.40) HDAC3HDAC4HDAC1HDAC6SYK
SCHEMBL6993531 0.85 SERPINE1 (0.37) HDAC3HDAC4HDAC1HDAC6SYK
SCHEMBL7000492 0.85 SERPINE1 (0.37) HDAC3HDAC4HDAC1HDAC6SYK
SCHEMBL6993528 0.85 SERPINE1 (0.37) HDAC3HDAC4HDAC1HDAC6SYK
SCHEMBL6986607 0.84 SERPINE1 (0.37) HDAC3HDAC4HDAC1HDAC6SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0846111-B1 SYNTHESES OF OPTICALLY PURE COMPOUNDS USEFUL AS GARFT INHIBITORS AND THEIR INTERMEDIATES AGOURON PHARMA (US) 2003-08-27 EP disclosed
US-5981748-A Synthesis of optically pure compounds useful as GARFT inhibitors and their intermediates AGOURON PHARMACEUTICALS, INC. (US) 1999-11-09 US disclosed
US-5831100-A Syntheses of optically pure compounds useful as GARFT inhibitors and their intermediates AGOURON PHARMACEUTICALS, INC. (US) 1998-11-03 US disclosed
EP-0846111-A1 SYNTHESES OF OPTICALLY PURE COMPOUNDS USEFUL AS GARFT INHIBITORS AND THEIR INTERMEDIATES AGOURON PHARMACEUTICALS, INC. (US) 1998-06-10 EP disclosed
WO-1996040674-A1 SYNTHESES OF OPTICALLY PURE COMPOUNDS USEFUL AS GARFT INHIBITORS AND THEIR INTERMEDIATES AGOURON PHARMACEUTICALS, INC. (US) 1996-12-19 WO disclosed